1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.14740/cr955" target="_blank" rel="noreferrer noopener">http://doi.org/10.14740/cr955</a>
Pages
76-88
Issue
2
Volume
11
ISSN
1923-2829 1923-2829
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.14740/cr955" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.14740/cr955</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
June 2020 Update I
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Internal Medicine
Affiliated Hospital
Cleveland Clinic Akron General Hospital
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome.
Publisher
An entity responsible for making the resource available
Cardiology research
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
2020-04
Subject
The topic of the resource
cardiac resynchronization therapy; Cardiorenal syndrome; cardiovascular events; Chronic kidney disease; Chronic kidney disease; decompensated heart-failure; Heart failure; impact; left-ventricular dysfunction; preserved ejection fraction; risk; vasopressin; worsening renal-function
Creator
An entity primarily responsible for making the resource
Raina Rupesh; Nair Nikhil; Chakraborty Ronith; Nemer Lena; Dasgupta Rahul; Varian Kenneth
Description
An account of the resource
Cardiorenal syndrome (CRS) encompasses various disorders of the heart and kidneys; dysfunction of one organ leads to acute or chronic dysfunction of the other. It incorporates the intersection of heart-kidney interactions across several mediums, hemodynamically, through the alterations in neurohormonal markers, and increased venous and renal pressure, all of which are hallmarks of its clinical phenotypes. This article explores the epidemiology, pathology, classification and treatment of each type of CRS.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.14740/cr955" target="_blank" rel="noreferrer noopener">10.14740/cr955</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
The file format, physical medium, or dimensions of the resource
journalArticle
2020
cardiac resynchronization therapy
Cardiology research
Cardiorenal syndrome
cardiovascular events
Chakraborty Ronith
Chronic kidney disease
Cleveland Clinic Akron General Hospital
Dasgupta Rahul
decompensated heart-failure
Department of Internal Medicine
Heart failure
impact
Journal Article
journalArticle
June 2020 Update I
left-ventricular dysfunction
Nair Nikhil
Nemer Lena
NEOMED College of Medicine
preserved ejection fraction
Raina Rupesh
Risk
Varian Kenneth
vasopressin
worsening renal-function
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.14740/cr553w" target="_blank" rel="noreferrer noopener">http://doi.org/10.14740/cr553w</a>
Pages
87–95
Issue
3
Volume
8
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.
Publisher
An entity responsible for making the resource available
Cardiology research
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
2017-06
Subject
The topic of the resource
Arginine vasopressin; Cardiorenal syndrome; Conivaptan; Heart failure; Tolvaptan; Vaptans; Vasopressin receptor antagonists
Creator
An entity primarily responsible for making the resource
Vinod Poornima; Krishnappa Vinod; Chauvin Abigail M; Khare Anshika; Raina Rupesh
Description
An account of the resource
Heart and kidney failure continued to be of increasing prevalence in today's society, and their comorbidity has synergistic effect on the morbidity and mortality of patients. Cardiorenal syndrome (CRS) is a complex disease with multifactorial pathophysiology. Better understanding of this pathophysiological network is crucial for the successful intervention to prevent advancement of the disease process. One of the major factors in this process is neurohormonal activation, predominantly involving renin-angiotensin-aldosterone system (RAAS) and arginine vasopressin (AVP). Heart failure causes reduced cardiac output/cardiac index (CO/CI) and fall in renal perfusion pressures resulting in activation of baroreceptors and RAAS, respectively. Activated baroreceptors and RAAS stimulate the release of AVP (non-osmotic pathway), which acts on V2 receptors located in the renal collecting ducts, causing fluid retention and deterioration of heart failure. Effective blockade of AVP action on V2 receptors has emerged as a potential treatment option in volume overload conditions especially in the setting of hyponatremia. Vasopressin receptor antagonists (VRAs), such as vaptans, are potent aquaretics causing electrolyte-free water diuresis without significant electrolyte abnormalities. Vaptans are useful in hypervolemic hyponatremic conditions like heart failure and liver cirrhosis, and euvolemic hyponatremic conditions like syndrome of inappropriate anti-diuretic hormone secretion. Tolvaptan and conivaptan are pharmaceutical agents that are available for the treatment of these conditions.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.14740/cr553w" target="_blank" rel="noreferrer noopener">10.14740/cr553w</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
Arginine vasopressin
Cardiology research
Cardiorenal syndrome
Chauvin Abigail M
Conivaptan
Department of Internal Medicine
Heart failure
Khare Anshika
Krishnappa Vinod
NEOMED College of Graduate Studies Student
NEOMED College of Medicine
Raina Rupesh
Tolvaptan
Vaptans
Vasopressin receptor antagonists
Vinod Poornima